|
BIO to Host Wall Street Briefing on Novel Industrial
Biotechnology
Third Annual Briefing on Industrial Biotechnology
to Highlight 'Green Investing' Opportunities
WASHINGTON, Feb 01, 2005 /PRNewswire via COMTEX/ -- The Biotechnology
Industry Organization (BIO) will host the third annual briefing on
industrial biotechnology for securities analysts and investors on Feb. 22,
2005. The half-day briefing will emphasize progress in the growing
industrial enzyme, small molecule production, nanotechnology, bioenergy and
biobased materials markets. Presentations will also highlight investment
opportunities in "green" technologies, such as the production of
clean-burning ethanol and cleaner manufacturing using biotech. The
invitation-only event will take place from 11:00 a.m. to 4:00 p.m. at the
Waldorf=Astoria Hotel in New York City.
Analysts and investors interested in attending should contact Sarah Lux at
(212) 362-1200 or send an email with contact information to
sarah@sternir.com.
Attendees of the Third Wave 2005 briefing will learn how industrial
biotechnology is rapidly transforming multiple industries, creating new
value chains and producing novel solutions to economic and environmental
problems.
Panel sessions will feature senior management from DuPont, Diversa, DSM,
Dyadic International, Iogen, Genencor International, Novozymes and Metabolix
discussing the following topics:
* Industrial Biotechnology Drug Discovery and Production;
* Industrial Enzymes for Cleaner Manufacturing and Chemical Synthesis;
* Innovative Solutions for Polymer Production; and
* New Biotech Production Methods for Ethanol Transportation Fuel.
Confirmed panel participants include Jean-Jacques Bienaime, chairman,
president and CEO of Genencor International; Steen Riisgaard, president and
CEO of Novozymes; James Barber, president and CEO of Metabolix; Mark
Emalfarb, CEO of Dyadic International; Jay Short, president and CEO of
Diversa; Maurice Hladik, director of marketing at Iogen; John Ranieri Vice
President DuPont, Colja Laane, Vice Presdient DSM, and speakers from
Portfolio 21 and other green investment funds.
BIO represents more than 1,000 biotechnology companies, academic
institutions, state biotechnology centers and related organizations in all
50 U.S. states and 33 other nations. BIO members are involved in the
research and development of health-care, agricultural, industrial and
environmental biotechnology products.
SOURCE Biotechnology Industry Organization
Paul Winters of the Biotechnology Industry Organization, +1-202-962-9237
|
|
